Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors

• Asıl Yazarlar: Laura L. Hammitt (Yazar), Dean Quinn (Yazar), Ewa Janczewska (Yazar), Francisco J. Pasquel (Yazar), Richard Tytus (Yazar), K. Rajender Reddy (Yazar), Katia Abarca (Yazar), Ilsiyar M. Khaertynova (Yazar), Ron Dagan (Yazar), Rachel Dawson (Yazar), Jennifer McCauley (Yazar), Tulin Shekar (Yazar), Wei Fu (Yazar), Alison Pedley (Yazar), Tina Sterling (Yazar), Gretchen Tamms (Yazar), Luwy Musey (Yazar), Ulrike K. Buchwald (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2023-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for at-r...